ÌÇÐÄvlog´«Ã½

Erectile Dysfunction Drugs Market Analysis

The Erectile Dysfunction Drugs Market size is estimated at USD 4.52 billion in 2024, and is expected to reach USD 6.36 billion by 2029, growing at a CAGR of 7.06% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the market owing to the underlying disease caused by the adverse effects of COVID-19 leading to the rising prevalence of erectile dysfunction. According to an article published by WebMed, in April 2021, COVID-19 increases the risk of developing erectile dysfunction (ED) by nearly six times. The estimated risk of developing ED was 5.66 times higher in men with a history of COVID-19. Its prevalence in the male COVID-19 group was estimated to be 31.8%. Access to the delivery of elective and non-emergency medical treatment was hampered by COVID-19, particularly during times of significant SARS-CoV-2 community transmission. During the COVID-19 outbreak, numerous elective operations for benign urological disorders like ED were postponed. Additionally, a significant trend toward management providing largely virtual care for issues related to men's sexual health has been seen, with procedures only being offered for emergencies and urgent cancer situations. According to an article published by ScienceDirect, in June 2021, there were 4.4% of video visits of patients for ED in 2020 as compared to 4.5% of office visits in 2019. The article stated that the outpatient population for ED treatment was unaffected by the use of telemedicine. Thus, people opting for telemedicine for the treatment of ED increased substantially. However, currently, as there is better access to erectile dysfunction drugs as compared to the initial pandemic times due to the lockdown, the market is expected to gain its growth pace over the coming 3-4 years.

Factors driving the erectile dysfunction (ED) drugs market include the adoption of a sedentary lifestyle and associated stress, the rising geriatric population, and the comorbidity between erectile dysfunction and heart disease and diabetes. A sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. According to the study published by BMC Endocrine Disorders, in July 2021, alcohol consumption, poor glycemic control, age, and diabetes duration were all found to be predictors of erectile dysfunction. Erectile dysfunction was found to be prevalent in 72.2% of people globally, in 2021. Thus, old age, diabetes, alcohol consumption, and poor glycemic control were found to have a significance on erectile dysfunction, thereby driving the market growth.

Erectile dysfunction is the most common risk factor in men, and its incidence increases with age. Aging and older men frequently have comorbidities, like diabetes mellitus, chronic obstructive pulmonary disease, hypertension, cardiovascular diseases, and many others; likewise, they concurrently refer to a clinician for impairments in sexual function, mostly for erectile dysfunction (ED). For instance, according to the article published by the NIH, in June 2021, sexual dysfunctions are common in people with diabetes and may arise from a variety of vascular, neurologic, and hormonal derangements. Furthermore, the rise in the number of ED cases is often correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is additionally another major illness linked to male erectile dysfunction. As reported by the WHO in 2021, the prevalence of hypertension has grown at a substantial rate and an estimated 1.28 billion adults aged 30 to 79 years have been affected by hypertension, with the majority (two-thirds) living in low- and middle-income countries. Hence, the increase in the prevalence of erectile dysfunction is likely to create a demand for drugs to treat the dysfunction, which is boosting the market growth.

However, the reluctance of patients to seek treatment and poor patient adherence to ED drugs are the factors restraining the market growth.

Erectile Dysfunction Drugs Market Trends

The Viagra (sildenafil citrate) Segment is Expected to Dominate the Market

Erectile Dysfunction Drugs Industry Segmentation

As per the scope of this report, erectile dysfunction is a very common condition, and it can be defined as the inability to maintain an erection sufficient for sexual intercourse. The Erectile Dysfunction Drugs Market is segmented By Product (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros, and Other Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.